Clinicians should consider using PCSK9 inhibitors to lower cholesterol in patients with statin-associated autoimmune myopathy. Findings from a case report are published in the Annals of Internal Medicine.

Beyond its toxic effect, statin use has been associated with a rare but potentially severe and disabling type of muscle disease known as statin-associated autoimmune myopathy. Its distinguishing features are the persistence after withdrawal of statins and its association with antibodies against 3-hydroxy-3methylglutaryl coenzyme A reductase (HMGCR). Management usually requires steroids and other immunosuppressive therapies. Other cholesterol-lowering medications and dietary supplements can cause or worsen this myopathy, which makes decreasing cholesterol levels very challenging in these patients. Treatment with PCSK9 monoclonal antibodies is a relatively new way to decrease cholesterol levels and cardiovascular morbidity and mortality in high-risk patients.

Researchers from University Hospital Principe de Asturias, Madrid, Spain, treated two male patients with hypercholesterolemia and severe, diffuse coronary artery disease who received prolonged treatment with a statin and developed an insidious and necrotizing autoimmune myopathy. Both patients were treated with steroids, immunosuppressive drugs, and intravenous immunoglobulins and all myopathy manifestations gradually resolved. Because the patients still needed cholesterol treatment, they were given evolocumab, a monoclonal antibody against PCSK9. Their LDL cholesterol levels decreased 55% in one patient and 56.4% in the other, and neither had a recurrence of myopathy. According to the researchers, the drugs' specific mechanism of action and these findings suggest that clinicians should consider using PCSK9 inhibitors in patients who develop statin-associated autoimmune myopathy and need treatment to decrease their cholesterol levels because of their high risk for coronary artery disease.